Application of PCSK9 Inhibitors in Practice
- 4 January 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 124 (1), 32-37
- https://doi.org/10.1161/circresaha.118.314191
Abstract
PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are set to revolutionize the treatment of hypercholesterolemia in the management of atherosclerotic risk, but numerous reports have detailed unprecedented barriers to access for these drugs. To overcome these challenges, our group created a model to facilitate provision of this new therapy for patients who qualify according to Food and Drug Administration criteria. This report details the real-world follow-up experience of PCSK9i use in a large patient cohort structured to ensure rigor in data collection, analysis, and interpretation. The 271 patients approved and actively followed in our PCSK9i clinic between July 2015 and August 2018 represent a 97% approval rate from insurance, with 28% of prescriptions requiring at least one appeal. Over 50% of patients were statin intolerant. On average, there was a median lapse of 15 days between initial visit and insurance approval. PCSK9i therapy was affordable for most patients, with an average monthly out-of-pocket expense of $58.05 (median $0). Only 2.3% of patients were unable to initiate or continue therapy because of cost. Reductions from baseline in LDL (low-density lipoprotein) cholesterol and Lp(a) (lipoprotein [a])were comparable to published reports with median reductions of 60% and 23% at 1 year, respectively. PCSK9i therapy was well-tolerated overall, though 9% of patients reported adverse events, and 5% of patients discontinued due mostly to musculoskeletal and flu-like symptoms. Our practice model demonstrates that PCSK9i therapy can be accessed easily and affordably for the majority of eligible patients, resulting in dramatic improvement in lipid profile results. Moreover, our registry data suggest that results from the prospective clinical trials of PCSK9i on LDL and Lp(a) reduction and on tolerability are applicable to a real-world cohort.Keywords
This publication has 24 references indexed in Scilit:
- Application of PCSK9 Inhibitors in PracticeCirculation Research, 2017
- Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid AssociationJournal of Clinical Lipidology, 2017
- Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)Circulation, 2017
- Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular DiseaseCirculation, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 2017
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsThe New England Journal of Medicine, 2017
- PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payersClinical Cardiology, 2017
- First endocardial rotor ablation using a 64-pole basket catheter in a patient with a left atrial appendage closure deviceEuropean Heart Journal, 2017
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseJAMA, 2016
- PCSK9 Association With Lipoprotein(a)Circulation Research, 2016